Showing results (1-10 of 79) with videos related to
Sort By:
Pageof 8
Methods in Molecular Biology (Clifton, N.J.)|July 2, 2013
Understanding microglia-neuron cross talk: relevance of the microglia-neuron coculturesFernando G Correa, Miriam Hernangómez, Carmen GuazaNeuropharmacology|May 8, 2012
A CB₁/CB₂ receptor agonist, WIN 55,212-2, exerts its therapeutic effect in a viral autoimmune model of multiple sclerosis by restoring self-tolerance to myelinAngel Arevalo-Martin, Eduardo Molina-Holgado, Carmen GuazaBritish Journal of Pharmacology|April 12, 2005
Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signalingFernando Correa, Leyre Mestre, Fabian Docagne, et al.Glia|May 28, 2005
Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte culturesSilvia Ortega-Gutiérrez, Eduardo Molina-Holgado, Carmen GuazaTrends in Molecular Medicine|May 14, 2017
Should We Stop Saying 'Glia' and 'Neuroinflammation'?Roser Masgrau, Carmen Guaza, Richard M Ransohoff, et al.Experimental Neurology|January 15, 2010
Aggravated experimental autoimmune encephalomyelitis in IL-15 knockout miceDiego Gomez-Nicola, Alessandra Spagnolo, Carmen Guaza, et al.Biochemical Pharmacology|August 18, 2006
The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infectionLeyre Mestre, Fernando Correa, Fabian Docagne, et al.Vitamins and Hormones|August 4, 2009
The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosisFernando G Correa, Leyre Mestre, Fabián Docagne, et al.Journal of Neurochemistry|December 11, 2002
Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filamentsFélix Hernández, José Borrell, Carmen Guaza, et al.International Journal of Molecular Sciences|November 26, 2022
The Dual PDE7-GSK3β Inhibitor, VP3.15, as Neuroprotective Disease-Modifying Treatment in a Model of Primary Progressive Multiple SclerosisRocio Benítez-Fernández, Carmen Gil, Carmen Guaza, et al.Pageof 8